TROMS0, Norway--(BUSINESS WIRE)--The Scandinavian-based drug development company Lytix Biopharma announced its intention to out-licence its lead candidates of ultra-broad spectrum synthetic antimicrobial peptidomimetics (SAMPs™), effective against bacteria as well as fungi. In addition to being broadly effective against even highly resistant strains such as MRSA, this novel class of small molecules exhibits an extremely low propensity for resistance development.
